Oragenics Implements 1-for-30 Reverse Stock Split to Enhance Market Position

Oragenics Inc., a development-stage biotechnology company, has announced a 1-for-30 reverse stock split of its common shares, effective June 3, 2025. The strategic financial move will consolidate every 30 existing shares into a single share, with the goal of increasing the company's share price and improving its appeal to potential investors.

The reverse stock split will occur under the existing NYSE American stock symbol 'OGEN' and will be accompanied by a new CUSIP number. According to CEO Janet Huffman, this action is part of the company's broader strategy to enhance its capital markets positioning while continuing to advance its research in neurological and infectious disease treatments.

Oragenics is currently focused on developing nasal delivery pharmaceutical medications, with specific emphasis on treatments for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC). By implementing this reverse stock split, the company aims to signal financial stability and attract sophisticated investors interested in its innovative medical research.

Reverse stock splits are typically used by companies to increase their stock price and meet minimum listing requirements on major exchanges. While the total market capitalization remains unchanged, the move can help improve market perception and potentially reduce stock price volatility.

The company's strategic approach suggests a commitment to long-term growth and financial discipline in the competitive biotechnology sector. Investors and market analysts will likely be monitoring the impact of this stock split on Oragenics' market performance and research development trajectory.